EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients

Lucia Di Nardo, Laura Del Regno, Alessandro Di Stefani, Maria Mannino, Barbara Fossati, Silvia Catapano, Laura Quattrini, Cristina Pellegrini, Alessio Cortellini iD, Alessandro Parisi, Ettore Capoluongo, Chiara Autilio and 2 more

Experimental Dermatology · 2023

DOI: 10.1111/exd.14901 ↗

At a glance

Journal article in Experimental Dermatology, 2023. Written by Lucia Di Nardo and 13 co-authors. Institution: Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. Major MEDLINE topics: Melanoma, Circulating Tumor DNA, Proto-Oncogene Proteins B-raf, Skin Neoplasms. Cited 9 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Despite the introduction of targeted (BRAFi/MEKi) and immune checkpoint inhibitors (ICIs) has significantly reduced the recurrence rate and improved the overall survival (OS) of patients with Stage III and IV melanoma, only a percentage will benefit of durable disease control. The aim of this study was to examine whether the levels of circulating tumour DNA (ctDNA) in plasma of advanced melanoma patients undergoing BRAFi/MEKi or ICIs vary according to the patients' survival outcomes (i.e. progression‐free survival (PFS) and OS) and disease progression. Plasma samples of Stage III‐IV melanoma patients were collected at baseline (treatment initiation) and thereafter every 3 months. Circulating BRAF V600E/K and NRAS Q61R/K mutations were analysed through droplet digital PCR (ddPCR, Bio‐Rad) in a total of 177 plasma samples from 48 melanoma patients (19 Stage III, 29 Stage IV). Baseline ctDNA concentration was significantly associated with OS (HR = 1.003, 95% CI = 1.000–1.006, p = 0.043) and PFS (HR = 1.004, 95% CI = 1.000–1.007, p = 0.029) independent of clinical‐prognostic confounders. For each unit increase in the ∆ctDNA (concentration difference between the last follow‐up and baseline) there was a 24% increased risk of disease progression, irrespective of treatment type and stage at diagnosis (OR = 1.24, 95% CI = 1.03–1.49, p = 0.020, AUC = 0.93). Patients with reduction of ctDNA level from baseline to the last follow‐up had longer OS (HR = 0.14; 95% CI = 0.05–0.44, p = 0.001) and PFS (HR = 0.08; 95% CI = 0.03–0.27, p < 0.0001) compared to patients with increased ctDNA, including adjustment for confounding factors. Our findings suggest that variation of ctDNA over time during melanoma treatment reflects the clinical outcome and tumour response to therapy and might be helpful in clinical monitoring.

Subjects

MeSH terms (MEDLINE)

MelanomaCirculating Tumor DNAProto-Oncogene Proteins B-rafSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultImmune Checkpoint InhibitorsMutationDisease ProgressionProgression-Free SurvivalNeoplasm StagingProtein Kinase InhibitorsAged, 80 and overGTP PhosphohydrolasesMembrane Proteins

Author keywords

circulating tumour DNAfollow-up studiesimmune checkpoint inhibitorsmelanomaprogression-free survival

Substances

Circulating Tumor DNAProto-Oncogene Proteins B-rafBRAF protein, humanImmune Checkpoint InhibitorsNRAS protein, humanProtein Kinase InhibitorsGTP PhosphohydrolasesMembrane Proteins

Authors and institutions

  • Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A, Gemelli - IRCCS, Rome, Italy.
  • Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Medical Oncology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Department of Surgery & Cancer, Imperial College London, London, UK.
  • Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.

ORCID profiles: Alessio Cortellini

Cite

APA

Di Nardo, L., Del Regno, L., Di Stefani, A., Mannino, M., Fossati, B., Catapano, S., Quattrini, L., Pellegrini, C., Cortellini, A., Parisi, A., Capoluongo, E., Autilio, C., Fargnoli, M. C., & Peris, K. (2023). The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. https://doi.org/10.1111/exd.14901

Vancouver

Di Nardo L, Del Regno L, Di Stefani A, Mannino M, Fossati B, Catapano S, et al. The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. 2023. doi:10.1111/exd.14901

BibTeX
@article{DiNardo2023,
  author = {Di Nardo, Lucia and Del Regno, Laura and Di Stefani, Alessandro and Mannino, Maria and Fossati, Barbara and Catapano, Silvia and Quattrini, Laura and Pellegrini, Cristina and Cortellini, Alessio and Parisi, Alessandro and Capoluongo, Ettore and Autilio, Chiara and Fargnoli, Maria Concetta and Peris, Ketty},
  title = {The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14901}
}
Start for free →